A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Maria AlsinaFernando RiveraFrancisco Javier RamosMaica GalánRafael LópezPilar García-AlfonsoJosé Enrique Alés-MartinezBernardo QueraltAntonio AntónAlfredo CarratoCristina GrávalosMaria José Méndez-VidalCarlos LópezInmaculada Ruiz de MenaJosep TaberneroJordi GiraltEnrique Arandanull nullPublished in: Targeted oncology (2019)
Neoadjuvant cetuximab/TPF followed by chemoradiotherapy in locoregional oesophageal carcinoma patients is feasible and offers a modest response rate in this trial. The results of combining trimodality neoadjuvant treatment with cetuximab are consistent with the literature. Registration: The study is registered at ClinicalTrials.gov (NCT00733889).
Keyphrases
- locally advanced
- phase ii study
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- ejection fraction
- chronic kidney disease
- systematic review
- newly diagnosed
- clinical trial
- prognostic factors
- randomized controlled trial
- metastatic colorectal cancer
- replacement therapy
- open label
- smoking cessation
- muscle invasive bladder cancer